Ekso Bionics Stock Price, News & Analysis

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported record preliminary revenue for Q4 2021 between $3.9 million and $4.1 million, showing a 77% increase from Q4 2020's $2.3 million. Total revenue for fiscal 2021 reached an estimated $11.1 million to $11.3 million, up 26% from $8.9 million in 2020. Cash on hand surged to $40.4 million from $12.9 million a year earlier. CEO Jack Peurach indicated strong growth in both rehabilitation and industrial sectors, enhancing their market presence.

Ekso Bionics, a leader in exoskeleton technology, announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The management will engage in a fireside chat available on-demand starting January 10 at 4:00 AM PT. This chat will be accessible throughout the conference on the company's investor website. Founded in 2005, Ekso Bionics aims to enhance strength and mobility through innovative wearable robots. The company is publicly traded on Nasdaq under the symbol EKSO.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) has appointed Corinna E. Lathan, Ph.D., to its Board of Directors. Dr. Lathan brings over 20 years of experience in robotics and biomedical engineering, having co-founded AnthroTronix. She currently serves on the board of PTC, Inc. and has held academic positions at prominent universities. CEO Jack Peurach expressed confidence in Dr. Lathan's ability to provide unique insights as the company aims to advance its innovative exoskeleton technologies for medical and industrial applications.

Ekso Bionics Holdings announced a significant partnership with the Fraternal Order of Eagles to enhance patient care in Nebraska. The EksoNR devices will be donated to Bryan Medical Center and Nebraska Methodist Hospital, benefiting over 60% of patients. This innovative technology aims to improve rehabilitation outcomes for patients with spinal cord injuries, strokes, and brain injuries. The initiative underscores Ekso's commitment to advanced rehabilitation and support for healthcare providers.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported a revenue of $3.0 million for Q3 2021, a slight increase from $2.9 million in Q3 2020. The gross margin was approximately 59%, down from 63% the previous year. The company booked 16 EksoNR units and maintained a strong cash position of $43.4 million. Despite increased revenues from EksoHealth, the net loss applicable to common stockholders for the quarter was $2.0 million, contrasting with a net income of $2.5 million during the same period in 2020.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its financial and business results for Q3 2021 on November 2, after market close. Management will discuss these results in a conference call at 1:30 p.m. PT/4:30 p.m. ET. A live webcast will be accessible in the 'Investors' section on the company's website. For those unable to attend, a replay will be available for two weeks. Ekso Bionics specializes in exoskeleton solutions for medical and industrial applications, enhancing strength and mobility for users.

Ekso Bionics Holdings, listed on Nasdaq as EKSO, announced its participation in a fireside chat at the H.C. Wainwright 23rd Annual Global Investor Conference from September 13-15, 2021. The chat will be available on-demand starting at 4:00 AM PT / 7:00 AM ET on September 13, allowing investors to access insights into the company's exoskeleton technology for medical and industrial purposes. Founded in 2005, Ekso Bionics focuses on innovative solutions to enhance mobility and strength.

Ekso Bionics Holdings reported Q2 2021 revenue of $2.2 million, slightly down from $2.3 million in Q2 2020. The gross margin improved to approximately 58% from 56% year-over-year, driven by better margins on EksoWorks products. Notably, the company successfully booked 20 EksoNR units, including 11 subscriptions. Despite an increased net loss of $1.3 million compared to $11.8 million in Q2 2020, the company holds a strong cash position of $45.9 million as of June 30, 2021, indicating stable financial health.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its Q2 2021 financial results on July 29, 2021, after market close. A conference call will follow at 1:30 p.m. PT to discuss the results and recent business developments. Investors can access a live webcast on the company's website. A replay will be available for two weeks post-call. Ekso Bionics specializes in exoskeleton technology for medical and industrial applications, aiming to enhance human capabilities. The company is headquartered in the San Francisco Bay Area.